Compliance and Traceability in Drug Manufacturing
Feb. 14, 2007
What was once viewed as a necessary evil or a cost of doing business is increasingly being seen as a key competitive advantage, although hurdles remain.
Click the Download Now button below to access this 6-page, 2.6 MB pdf document.
About the Author
Matthew Littlefield | Manufacturing Research Analyst
Latest from cGMPs
Key considerations for CGMP raw materials compliance
Intas hit with FDA warning letter
Beyond ‘good’ practices
Biocon hit with multiple 483s
Developing a cell and gene therapy packaging strategy
Toward a collaborative pharma ecosystem
Load More Content